Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea (NCT00696111), a na na study. The primary outcome is Estrogen Levels.

2. Clinical Question

These details define a question about metabolic and hormonal characterization, but they do not establish an estimable treatment effect. The intervention description includes a sequence involving Lupron and estrogen plus placebo, while the study is classified as single group and its allocation is NA. The record therefore does not support interpreting the intervention as one side of a controlled comparison. The description of randomization within the arm narrative does not supply evidence of a separate comparator or a group-level contrast.

The primary endpoint is a continuous measurement, but the record does not report its numerical outcome. In addition, the primary-outcome description identifies zero patients in Specific Aim 2 after the patient randomized to Lupron dropped out. The record does not clarify how that fact relates to the baseline endpoint population or provide another analysis population with outcome values. As a result, the clinical question can be described from the study purpose and endpoint definition, but the posted record cannot answer whether the intervention sequence changed estrogen levels or how large any change might have been.

3. Trial Design

The study is titled “Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea,” and its official title is “PCOS, Sleep Apnea and Metabolic Risk in Women.” Its stated purpose is to examine metabolic and hormonal features of sleep problems in women with polycystic ovary syndrome. The record lists polycystic ovary syndrome and obstructive sleep apnea as conditions. The phase is NA, allocation is NA, masking is none, and the model is single group. Enrollment is 18.

The listed intervention is a drug sequence named Depot Lupron followed by estrogen plus placebo. The arm description states that participants were randomized to receive depot Lupron for 6 weeks and then randomized again to receive estrogen plus placebo for another 6 weeks. However, the record classifies the study as single group and does not list a like-for-like control comparison. It does not provide a detailed account of the sequence’s allocation, the numbers assigned to each treatment, or a separate control arm. The arm narrative and the overall design classification should therefore not be treated as enough information to infer a randomized comparison.

The primary outcome is estrogen levels at baseline. The description says measurements were taken every 20 minutes over 24 hours and that the average of those values is presented. The measurement unit is pg/ml. Intravenous Glucose Tolerance Test is listed as a secondary outcome. The registry record notes four outcome measures and zero analyses, but does not report numerical results for the primary endpoint.

The status is completed. The study start is recorded as 2007-12 and primary completion as 2022-06-30. The sponsor is the University of Chicago. These administrative details describe the record’s study status and registration, but do not substitute for outcome estimates. In particular, completion status does not establish that a primary endpoint was reported or analyzed. The stated primary-outcome population for Specific Aim 2 is zero because the one patient randomized to Lupron dropped out. No further explanation of the analysis population or the consequences for other aims is reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The number of patients in Specific Aim 2 is zero, since the one patient randomized to Lupron dropped out.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Estrogen Levels, measured over Baseline.

The primary endpoint is estrogen levels at baseline, measured in pg/ml. According to the registry description, measurements were taken every 20 minutes for 24 hours, and the average of those measurements is the endpoint value. Thus, the endpoint is not described as one isolated blood measurement: it is a summary of repeated measurements across the stated observation period. The record does not report the actual mean or standard deviation for this endpoint.

Estrogen is a hormonal measure, and the study’s stated purpose is to examine metabolic and hormonal features of sleep problems in women with polycystic ovary syndrome. A continuous measure such as this can describe the level of a hormone in the study population and can be used to characterize the outcome numerically. In general, averaging repeated measurements can represent the overall level across the measurement period, while the standard deviation describes variation among the values included in the reported summary. These are general statistical interpretations; the registry record does not explain why this particular endpoint was selected or provide further biological justification.

The endpoint’s timeframe is baseline. That label describes when the primary outcome is specified; it does not itself give a before-and-after comparison. The record does not report a baseline value, a later value, a change from baseline, or an estimated contrast between treatment conditions. It also states that the number of patients in Specific Aim 2 was zero because the one patient randomized to Lupron dropped out. The record does not clarify whether the baseline endpoint was available for another aim or analysis population. Consequently, the endpoint is well described in terms of what was measured, but its observed distribution and its relation to the intervention cannot be evaluated from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is continuous and is described using a mean and standard deviation. In general, a mean represents the central level of a continuous measurement, while a standard deviation describes how spread out individual measurements are around that mean. These summaries answer different questions: the mean characterizes the level, and the standard deviation characterizes variability. Neither is reported numerically for estrogen levels in the registry record, so the outcome distribution cannot be reconstructed from the posted information.

What does the endpoint summarize?

The registry describes estrogen measurements taken every 20 minutes over 24 hours, with the average of those measurements presented as the endpoint. This produces a summary intended to represent the measurement period rather than any one time point. In general, repeated measurements can contain information about patterns over time, but reducing them to an average does not show the time course. The record does not report individual measurements, a profile across the period, or a method for handling missing measurements within the 24-hour series. No additional procedure should be inferred.

What can a confidence interval tell a reader?

In general, a confidence interval expresses the precision of an estimated quantity by giving a range of values compatible with the data and the method used. A narrow interval indicates greater precision than a wide interval, while an interval alone does not establish that a result is clinically important. The registry record does not report a confidence interval for estrogen levels or for a treatment contrast. Consequently, precision cannot be judged. A point estimate without an uncertainty measure would also be incomplete for assessing how stable an estimate may be, and no point estimate is reported.

Is there a valid treatment comparison?

The study is labeled single group, allocation is NA, and the record does not describe a like-for-like control comparison. The intervention narrative mentions randomization at two points in a sequence, but it does not supply a separate comparator group or a reported contrast. A comparison of treatment conditions generally requires clearly defined groups or conditions, outcome measurements for each, and an analysis that estimates the difference while accounting for the design. Those elements are not reported for this outcome. The intervention name’s reference to placebo does not establish that a placebo-only group existed.

What do the analysis entries establish?

The record lists zero analyses. This means no analysis results are available in the registry record for assessment; it does not identify whether analyses were planned elsewhere or performed outside the record. The primary endpoint’s named population for Specific Aim 2 is zero, because the one patient randomized to Lupron dropped out. The record does not explain how that population statement relates to the baseline endpoint or other aims. No statistical model, adjustment strategy, handling of repeated observations, or missing-data method is reported. Those methods should not be guessed.

How should planning illustrations be read?

General sample-size illustrations describe assumptions for hypothetical planning rather than observed trial performance. The record’s stated assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect set as a stated fraction of the observed effect. It also distinguishes participants per arm for ordinary outcomes from total events for time-to-event outcomes. These assumptions describe a planning framework, not a report of the trial’s design or achieved power. Any sample-size illustration is not observed power.

In this case, the record does not report a numerical observed effect for the primary outcome, nor does it report a treatment comparison from which such an effect could be assessed. It also describes the trial as single group rather than a two-arm comparison. Therefore, hypothetical planning assumptions should not be read as evidence that the study was designed with equal allocation, that it had two comparable groups, or that it could detect a particular effect. They cannot supply missing outcome data or replace a reported analysis.

Why does over-dispersion matter in general?

For outcomes analyzed with count-based models, over-dispersion occurs when the observed variability is greater than the model’s assumptions allow. In general, ignoring over-dispersion can make uncertainty estimates too small and statistical evidence appear stronger than it is. This concept is not directly applicable to the listed primary endpoint, which is a continuous measure summarized by a mean and standard deviation, and the record does not report a count-based primary analysis. It is a general modeling consideration, not a finding about this study.

No recalculated treatment estimate is reported. A simple unadjusted recalculation from posted summary statistics would require relevant group summaries and a comparison structure; those are not reported for estrogen levels. Without such data, there is no basis to recalculate an effect or its precision. The available information supports describing the endpoint and design limitations, not deriving an unreported result.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Specific Aim 1: Women Without Obstructive Sleep Ap", "Specific Aim 1: Women With Obstructive Sleep Apnea", "Specific Aim 3")
n   <- c(13, 5, 1)
m   <- c(73.3, 69.9, 61)
sp  <- c(32.5, 14.1, 18.2)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Specific Aim 1: Women Without Obstructive Sleep Ap  13  73.300  32.500  53.660  92.940
CARM  Specific Aim 1: Women With Obstructive Sleep Apnea  5  69.900  14.100  52.393  87.407
CARM  Specific Aim 3  1  61.000  18.200  NaN  NaN

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists four outcome measures and identifies estrogen levels as the primary outcome. Intravenous Glucose Tolerance Test is named as a secondary outcome. The record does not describe how many outcome measures were planned at each time point, how multiple hypotheses were handled, whether any outcomes were designated exploratory, or whether statistical significance was adjusted for multiple testing. This information is not reported in the registry record. Without a reported analysis plan or results, the implications of testing multiple outcomes cannot be evaluated.

The primary outcome is specified at baseline, and the record describes averaging estrogen measurements collected every 20 minutes over 24 hours. It does not report whether all measurements were available for each participant, how incomplete measurement series were handled, or whether any participants lacked baseline outcome data. No missing-data method, imputation procedure, or sensitivity analysis is reported. These details matter because missing outcome information can affect both the group represented by an estimate and the uncertainty around it. Their absence prevents assessment of how missingness may have influenced results.

The record states that the number of patients in Specific Aim 2 was zero because the one patient randomized to Lupron dropped out. It does not describe the analysis population for the other aims, nor does it state whether analyses were intended to include all enrolled participants, participants who began an intervention, or another defined population. The record lists zero analyses. Thus, no reported results are available to establish which participants contributed to an outcome estimate or whether exclusions were handled consistently.

There is also no reported statistical analysis plan describing covariate adjustment, repeated-measures modeling, interim analyses, or multiplicity control. Those procedures should not be inferred from the study’s purpose or from the intervention narrative. The registry record does not report them. In the absence of outcome estimates, analysis populations, and methods, readers cannot evaluate the robustness of a statistical conclusion. The appropriate interpretation is that these aspects remain undocumented in the registry record, not that a particular approach was or was not used outside it.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event entries are organized by Specific Aim. For Specific Aim 1, the record lists 18 at risk for serious adverse events and 18 at risk for other adverse events. The reported affected counts are zero for both categories, and deaths are zero. For Specific Aim 2, the at-risk counts are zero for both categories, with zero affected and zero deaths. For Specific Aim 3, one is listed at risk for each category, with zero affected and zero deaths. No serious adverse-event terms are listed.

These are registry counts, not comparative safety estimates. The study is classified as single group, and the record does not provide a like-for-like control group or an analysis comparing event frequencies between conditions. A zero affected count in a group with participants at risk means no events were reported in that entry; it does not establish that the underlying risk is zero. The record also does not provide event definitions, follow-up duration for safety reporting, or details about how events were collected.

Specific Aim 2 has no participants listed at risk, so its zero event count does not describe an observed event experience among participants in that aim. The record separately notes that the Specific Aim 2 population was zero because the one patient randomized to Lupron dropped out. These entries should not be interpreted as evidence that no safety concerns could occur, or as a treatment comparison. They describe only the counts recorded for the listed aims.

13. What the Result Does, and Does Not, Mean

The record documents a study focused on metabolic and hormonal features of sleep problems in women with polycystic ovary syndrome. It identifies estrogen levels at baseline as the primary outcome and describes a repeated-measurement procedure: measurements every 20 minutes over 24 hours, averaged and expressed in pg/ml. It also lists the Intravenous Glucose Tolerance Test as a secondary outcome. These details clarify the scientific topic and what the primary measurement was intended to represent.

The record does not report the primary endpoint’s mean or standard deviation, nor a confidence interval, p-value, or analysis comparing treatment conditions. It therefore does not show the magnitude or precision of an estrogen-level estimate. It also does not show whether the described intervention sequence changed estrogen levels. The absence of a reported result is not evidence that the result was null, favorable, or unfavorable. It means the registry record does not provide the information needed to make those judgments.

The design classification is single group, allocation is NA, and a like-for-like comparator is not described. Although the arm narrative refers to randomization to depot Lupron and then to estrogen plus placebo, the record does not identify a separate control group or report a between-group estimate. The intervention name alone cannot establish a controlled comparison. Consequently, the posted information cannot support a causal treatment-effect conclusion.

The record’s statement that the Specific Aim 2 population was zero because the one patient randomized to Lupron dropped out is a further constraint. It leaves unclear which population, if any, contributed to the baseline outcome, and the record lists zero analyses. The adverse-event counts report zero affected and zero deaths in the listed entries, but the zero at-risk count for Aim 2 cannot be treated as an observed safety experience for that aim. Counts from the other entries are descriptive and do not provide a comparative safety estimate.

In short, this record can be used to understand the study’s topic, registered endpoint, intervention description, and administrative status. It cannot establish the primary outcome’s observed level, an intervention effect, the precision of an estimate, or the presence or absence of a comparative safety difference. Conclusions beyond these descriptive points are not supported by the posted results.

14. Why This Trial Matters Statistically

This study is statistically instructive because it separates a clearly described measurement from a result that is not reported. Estrogen levels are defined in practical terms: repeated measurements every 20 minutes over 24 hours are averaged, with pg/ml as the unit. That definition helps readers understand the intended endpoint. Yet a precise endpoint description is not a substitute for a reported estimate, variation, or analysis. Without those quantities, the central statistical result remains unavailable.

The record also illustrates why design labels matter when interpreting treatment language. The intervention narrative describes randomization at successive stages, but the overall study is classified as single group, allocation is NA, and no like-for-like comparison is reported. Statistical claims about treatment effects depend on a clearly specified comparison and an analysis that corresponds to it. A placebo in an intervention name does not, on its own, define a control group. Readers should distinguish a treatment sequence from an estimable contrast.

The population statement for Specific Aim 2 is another important feature. The record says that its population was zero because the one patient randomized to Lupron dropped out. This highlights that enrollment does not automatically tell readers how many participants contributed to a particular endpoint or aim. Clear analysis-population reporting is essential for understanding which data support an estimate. Here, the record does not describe another outcome population or provide an analysis.

Finally, the safety entries demonstrate why event counts need their denominators and design context. The record reports at-risk and affected counts for each aim, but Aim 2 has zero at risk. Counts with no at-risk population cannot describe observed event experience for that aim. The other entries remain descriptive rather than comparative. Taken together, these features show that statistical interpretation depends not only on the clinical question and measurement, but also on outcome reporting, analysis populations, and a design that supports the intended comparison.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

A major limitation of the registry record is that it does not report numerical results for the primary outcome. Although the endpoint is defined as baseline estrogen levels averaged over measurements taken every 20 minutes for 24 hours, no mean or standard deviation is included. No confidence interval or inferential result is reported. Readers therefore cannot assess the outcome’s observed level, variability, or precision.

The record’s population information is incomplete for interpreting that endpoint. It states that the number of patients in Specific Aim 2 was zero because the one patient randomized to Lupron dropped out, but does not explain how this relates to the baseline outcome population or to the other aims. It does not report an analysis population, missing measurement procedures, or an account of whether the repeated measurements were complete. These omissions make it difficult to determine which data would support any estimate.

The design is also difficult to interpret from the available description. The overall model is single group and allocation is NA, while the arm narrative mentions randomization to depot Lupron and subsequent randomization to estrogen plus placebo. The record does not identify a separate comparator or give a between-group analysis. This prevents a controlled treatment-effect interpretation. The registry record does not report whether a statistical analysis plan specified another approach.

Additional limitations include the absence of reported methods for handling multiple outcomes, covariate adjustment, repeated measures, or missing data. The record lists four outcome measures but zero analyses. It does not provide detail on the timing or completeness of safety follow-up, adverse-event definitions, or collection methods. These gaps do not show that procedures were absent; they mean the relevant information is not reported in the registry record. The completed status and enrollment figure do not resolve the missing outcome and analysis details.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea — NCT00696111.
• Registry record last updated 2024-12-31; status last verified 2024-08.
• Results first posted 2024-12-31.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The record describes a completed, single-group study titled “Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea,” sponsored by the University of Chicago. It lists enrollment of 18, phase NA, allocation NA, and masking none. The stated purpose is to examine metabolic and hormonal features of sleep problems in women with polycystic ovary syndrome.

The listed intervention is Depot Lupron followed by estrogen plus placebo. The primary outcome is baseline estrogen levels in pg/ml, defined as the average of measurements collected every 20 minutes over 24 hours. Intravenous Glucose Tolerance Test is listed as a secondary outcome. The record states that the Specific Aim 2 population was zero because the one patient randomized to Lupron dropped out.

Numerical primary-outcome results and analyses are not reported in the registry record. Safety entries list zero affected and zero deaths, with at-risk counts that vary by aim; no serious adverse-event terms are listed. The record does not establish a separate control group or report a comparative treatment estimate.